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Abstract 
A variant of human prostate PC3 cells, isolated from PC3 cells, was shown to be significantly resistant (> lo-fold) to several 
clinically active anticancer drugs, including VP-16 and cisplatin. Previous studies showed that resistance to these drugs was not due to 
expression of the mdrl gene, or modifications in topoisomerases but may have resulted from high expressions of certain proto-oncogenes 
(Yamazaki et al. (1994) Biochim. Biophys. Acta 1226, 89-96). Flow cytometry, DNA gel electrophoresis and northern blot analysis were 
used to further characterize drug responses in sensitive and resistant cells. Treatment of the sensitive PC3 cells with VP-16 and CDDP 
resulted in accumulation of cells in S and G2, and Gl and S phases, respectively, and caused significant degradation of the genomic DNA 
into intemucleosomal sized DNA fragments, indicating apoptosis. In contrast, resistant PC3 cells showed little or no DNA fragmentation. 
Resistant PC3(R) cells expressed 2-3-fold more bc12 protein than the parental PC3 cells, and overexpressed c-myc, c-&n and H-ras 
mRNA compared to sensitive cells. Treatment with VP-16 or CDDP significantly induced c-myc mRNA levels in sensitive PC3 cells. 
H-rus message was not affected by either VP-16 or CDDP treatment in PC3 cells. These studies, taken together, suggest that a differential 
susceptibility to apoptosis and chemosensitivity may be related to altered levels of bc12 and/or oncogene overexpression in PC3(R) cells. 
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1. Introduction 
One of the major obstacles of effective treatment of 
cancers has been the emergence of broad-based drug resis- 
tance by tumor cells. The development of resistance to 
naturally occurring drugs, e.g., doxorubicin, often leads to 
the emergence of cross-resistance to a wide variety of 
drugs with different chemical structures and/or mecha- 
nisms of action [l]. The understanding of the biochemical, 
Abbreviations: MDR, multidrug resistance; Pgp, P170-glycoprotein; 
topo, topoisomerase; VP-16, etoposide; CDDP, cisplatin; MD, median 
dose; PC3(R), drug resistant PC3 cells; PBS, phosphate-buffered saline; 
M’lT, 3-(4,5-dimethyl-2-thiazolyl)_2,5-diphenyl-2H-tetr~olium bromide; 
DMSO, dimethylsulfoxide; SDS, sodium dodecyl sulfate; DTT, dithio- 
theitol. 
* Corresponding author. Fax: + 1 (301) 4023091. 
and pharmacological mechanisms of drug resistance in- 
cluding the acquired multidrug resistance (MDR) pheno- 
type is, therefore, critical for designing more effective 
treatment strategies. Several studies have indicated that the 
mechanism of MDR is multifactorial. Cells selected for 
high drug resistance generally show decreased intracellular 
drug accumulation due to overexpression of P-170 glyco- 
protein, have high levels of detoxification enzymes 
(glutathioneS-transferase and glutathione peroxidase), and 
decreased levels of activating enzymes, e.g., cytochome 
P-450 [2-61. Furthermore, recent studies indicate that bcZ2 
alone, and in co-operation with c-myc, can confer resis- 
tance against a wide variety of drugs by inhibiting apopto- 
sis [7-91. 
Recently, we have described a subpopulation of tumor 
[PC3(R)] cells, isolated from human prostate PC3 cells in 
culture [lo]. PC3 cells displayed two cell populations with 
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distinct cell morphology: one type consisted of flat epithe- 
lial-like cells and the other morphology consisted of round 
cells. The flat cells termed here as PC3(R) and round cells 
as PC3 cells were cloned by serial dilution as described 
previously [lo]. Previous studies to characterize these cells 
have shown that PC3(R) cells were resistant to several 
anticancer drugs including VP-16, adriamycin and CDDP; 
however, no known mechanisms of drug resistance, e.g., 
expression of mdrl or decrease or modification in the 
activity of topoisomerase I or II, could be demonstrated in 
PC3(R) cells [lo]. However, PC3(R) cells showed higher 
expressions of c-myc, c-jun and H-r-us compared to the 
drug-sensitive PC3 cells, indicating that these oncogenes 
may play a role in resistance in PC3(R) cells. 
In this report, we have further characterized the mecha- 
nism of resistance in PC3(R) cells by examining the 
effects of drugs (VP-16 and CDDP) in respect to cell cycle 
arrest, DNA fragmentation, and oncogene expressions. In 
addition, we examined the expression of bc12 protein 
using western blotting in these cells. Our studies indicate 
that elevated levels of oncogenes and bc12 protein in 
PC3(R) cells may be related to this de novo drug resis- 
tance mechanism. 
2. Materials and methods 
2.1. Cells 
Human prostate tumor PC3 cells were obtained from 
the American Type Culture Collection (Rockville, MD). 
The resistant (PC3(R)) cells were isolated from the parent 
cells during routine subcultivation as described previously 
[lo]. Both cells were maintained in RPM1 1640 medium 
supplemented with 10% fetal bovine serum (FBS) contain- 
ing antibiotic mixture at 37°C under a humidified 5% CO, 
atmosphere. 
2.2. Chemicals 
VP-16 was a gift from Bristol-Myers (Syracuse, NY). 
CDDP was obtained from the Drug Development Branch, 
National Cancer Institute, NIH, Bethesda, MD. MTT, DTT, 
and DMSO were purchased from Sigma (St. Louis, MO). 
2.3. Cytotoxicity assay 
The cytotoxicities of VP-16 and CDDP were evaluated 
by the MlT assay following continuous drug exposure for 
5-days [lO,ll]. Data were collected as replicates of six 
wells. VP-16 was dissolved in DMSO and CDDP was 
dissolved in PBS and the solutions were used immediately. 
Median dose values were determined from median effect 
plots: 
btmffected 1 [Dose] 
log [fraction”,,,,,,,,] = log [Dose median]” 
where m is the Hill-type coefficient of sigmoidicity as 
described by Chou and Talalay [12]. 
2.4. Cell cycle analysis 
For the cell cycle analysis, exponentially growing PC3, 
and PC3(R) cells were treated with VP-16 (5, and 50 /.LM 
for 24 and 48 h) or CDDP (5 and 10 PM for 24 and 48 h). 
Following the drug treatment cells (1 3 lo6 cells) were 
washed with ice-cold PBS and then fixed with 70% ethanol. 
After fixation, cells were washed with PBS and then 
transferred into 0.5 ml PBS containing RNAse and propid- 
ium iodide as described previously [ 131. Cell cycle analysis 
was performed on a Becton-Dickinson FACSCAN. 
2.5. DNA fragmentation assay 
The nucleosomal DNA degradation was assayed as 
described previously [ 141 with slight modification. Briefly, 
equal numbers of cells were seeded in 60 mm2 culture 
dishes and treated with different concentrations of VP-16 
or CDDP for 24, 48 and 72 h. Following the drug treat- 
ment, cells of a dish were collected by trypsinization and 
washed with ice-cold PBS. DNA was extracted by lysing 
cells with 5 mM Tris (pH 7.4), 5 mM EDTA, and 0.5% 
Triton X-100 for 2 h on ice. The lysate was centrifuged at 
27000 X g for 20 min. The supernatant was exposed to 
200 pg/ml proteinase K for 1 h at 50°C and extracted 
with phenol-chloroform. The aqueous layer was treated 
with 0.13 M NaCl and the DNA was precipitated overnight 
at -20°C with 2 ~01s. of ethanol. Following treatment 
with 1 mg/ml boiled bovine pancreatic RNAse for 1 h at 
50°C the total DNA from each sample was loaded in one 
well of a 2% (w/v) horizontal agarose gel containing 0.3 
mg/ml ethidium bromide. The gel was run in TBE buffer 
at 2.5 V/cm, and photographed under UV light with 
Polaroid 57 type film. 
2.6. Western blot analysis for bc12 
The presence or absence of bc12 protein in PC3 and 
PC3(R) cells was examined by the Western blot analysis 
using bc12 mouse antibodies according to the methods 
described by Reed et al. [15]. Briefly, PC3 cells were 
collected by trypsinization, washed with ice-cold PBS and 
lysed with lysis buffer. Equal amounts of proteins were run 
in 4-20% SDS-PAGE and transferred electrophoretically 
onto nitrocellulose membranes. Nitrocellulose membranes 
were further incubated with a mouse antibody against bc12 
protein (Dako, CA) for 2 h at room temperature. The 
membranes were rinsed with PBS, treated with secondary 
antibody (goat antimouse-HP) for 2 h and developed by a 
chemiluminescence reagent (Du Pont NEN) and the film 
was exposed for 30 s to detect the bc12 protein. 
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Fig. 1. Cytotoxic profiles of VP-16 (panel A) and CDDP (panel B) 
towards human prostate PC3 (0) and PC3(R) (W) cells as determined 
using the h4TT assay as described in Section 2. 
2.7. Northern blot analysis for proto-oncogenes 
cDNA probes (40-mers for c-myc, and c-jun) used in 
this study were obtained from Oncogene Science (Manhas- 
T=24 hrs T=48 hrs 
I I I I 
set, NY). c-DNA probes for actin, and H-ras were ob- 
tained from ONCOR (Gaithersburg, MD). To examine the 
effects of drug treatment on oncogene expressions, PC3 
and PC3(R) cells were treated with VP-16 or CDDP for 0, 
1 and 3 h and mRNA was isolated using the Mini RiboseTM 
mRNA isolation Kit (Becton Dickinson). Approx. 2 lug of 
mRNA were electrophoresed and transferred onto a nylon 
membrane. Hybridizations were carried out for 2 h with a 
32P-end labeled 40-mer or c-DNA probe using QuickHyb 
(Stratagene). The RNA loading was comparable for all 
lanes as quantitated by actin probing. The hybridization 
filter was washed twice in 2 X saline sodium citrate @SC) 
and 0.1% SDS at room temperature for 15 min and then 
washed once in 0.1 X SSC and 0.1% SDS at 60°C for 30 
min. The filter was developed at - 70°C for autoradio- 
graphy . 
3. Results 
The cytotoxicity curves, obtained by the MTT assay, for 
VP-16 and CDDP in PC3 cells are presented in Fig. 1. The 
data clearly shows that PC3(R) cells are significantly 
resistant to both VP-16 (20-25fold) and CDDP (g-10- 
fold). The respective IC,, (PM) values for VP-16 and 
CDDP in PC3 and PC3(R) cells were 1.7 f 0.7 and 40.5 + 
15.8 and 0.5 f 0.1 and 4.5 k 1.3, respectively. 
PC3 PC3(R) PC3 PC3( R) 
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Pig. 2. Cell cycle analysis of pC3 and PCS(R) cells following treatment with VP-16 (5 and 50 /-MI for 24 and 48 h. 
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Fig. 3. Cell cycle analysis of PC3 and PC3(R) cells following CDDP treatment (5 and 10 PM) for 24 and 48 h. 
Because the resistance pattern observed with PC3(R) 
cells did not appear to be related to any known mechanism 
[lo], we evaluated cell cycle responses of these cells to 
VP-16 and CDDP and the stability of cells while arrested. 
Our flow cytometry results are presented in Fig. 2. We 
found that low doses (5 PM) of VP-16 induced a block in 
S- and GZphases when measured at 24 h following the 
drug treatment of PC3 cells. By 48 h, PC3 cells appeared 
A 
1 2 3 4 5 6 7 8 9 1011121314 15 
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Fig. 4. Electrophoretic gel laddering analysis of cellular DNA isolated from PC3 and PC3(R) prostate cells following drug treatment for 24, 48 and 72 h. 
DNA was isolated and loaded onto the gel as described in Section 2. Panel A represents VP-16 treated cells. Lanes, 1 and 2 are untreated DNA from PC3 
and PC3(R) cells, respectively. Lanes 3, 5, 7, 9, 11 and 13 represent VP-16 (5 and 50 PM) treated PC3 cells at 24, 48 and 72 h; lanes 4, 6, 8, 10, 12 and 
14 represent VP-16 (5 and 50 PM) treated PC3(R) cells, respectively. Lane 15 represents standard 123-bp DNA which served as molecular weight 
markers. Panel B represents CDDP treated cells. Lane 1 is untreated PC3 cells. Lanes, 2, 4, 6, 8, 10 and 12 represent DNA from CDDP (5 and 10 PM) 
treated PC3 cells at 24, 48 and 72 h. Lanes 3, 5, 7, 9, 11 and 13 represents DNA from cells treated with CDDP (5 and 10 PM) at 24, 48 and 72 h. 
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to degrade their genomic DNA, as evidenced by increased 
number of cells exhibiting lower propidium iodide fluores- 
cence (FL2-A values). In contrast, PC3(R) cells at low 
doses VP-16 appeared less perturbed than the sensitive 
cells (Fig. 2). At high doses VP-16 (50 PM), both PC3 
and PC3(R) cells showed S and G2 phase arrest; however, 
a larger proportion of the drug-sensitive cells exhibited 
low molecular weight DNA than the resistant cells. Expo- 
sure of PC3 cells to CDDP caused an arrest of cells in Gl 
and/or early S phase and resulted in a significant degrada- 
tion of cellular DNA in PC3 cells (Fig. 3). PC3(R) cells 
did not exhibit any marked intracellular degradation of 
DNA following CDDP treatment. 
Cell cycle analysis indicated that PC3 and PC3(R) cells 
exhibited differential DNA degradation following drug 
treatment. We examined this possibility in more detail by 
performing a DNA fragmentation assay using agarose gel 
electrophoresis. As depicted in Fig. 4, both VP-16 and 
CDDP at low doses (5 PM) induced significant DNA 
degradation into oligonucleosomal sized DNA fragments; 
a common hallmark of apoptosis [16,17]. In contrast, and 
under identical conditions, very little internucleosomal 
DNA fragmentation was observed in PC3(R) cells. At high 
dose CDDP treatment (10 PM), a significant DNA ladder- 
ing was observed in PC3(R) cells only after 72 h, but not 
at 48 h (Fig. 4B). 
Protein bc12 has been reported to protect cells from 
apoptosis in various cell systems [8,9,18,19]. Therefore, 
we examined whether expression of bc12 was different 
between these two cell lines. As shown in Fig. 5, sensitive 
PC3 cells showed relatively (2-3-fold) less bc12 than 
PC3(R) cells. 
As previously reported [ 101, PC3(R) cells showed higher 
expressions of c-myc, c-jun and H-rus compared to the 
sensitive variants. Because proto-oncogenes and their pro- 
tein products have been reported to control cell growth and 
influence cell cycle progression [20,21], we examined the 
effects of VP-16 and CDDP on c-myc, c-jun and H-rus 
expression in PC3 cells. As depicted in Fig. 6, VP-16 
caused significant increases in c-myc expressions in PC3 
cells in a time-dependent manner. VP-16 treatment did not 
Fig. 5. Western blot analysis for bc12 protein expression in PC3 and 
PC#R) cells. 
123456 
c-jun 
Actin 
Fig. 6. expression and effects of VP-16 (100 PM) treatment for 1 and 3 
h. Prostate PC3 cells were treated with VP-16 for either 1 or 3 h, RNA 
was extracted and hybridized with appropriate 32P-labeled probes as 
described in Section 2. Actin probe was used for similar RNA loading. 
significantly altered expressions of c-jun or H-rus mRNA 
in either cell line. Similar results were obtained with 
CDDP (not shown). 
4. Discussion 
In this report we have examined several aspects of the 
response of prostate PC3 cell lines to the DNA damaging 
agents VP-16 and CDDP. Our goal in this investigation 
was to ascertain the molecular basis for differences in 
chemosensitivity between PC3 and PC!3(R) cell lines. While 
molecular studies have shown a role for oncogenes in 
deregulated proliferation and/or differentiation, the role of 
oncogenes in drug resistance has not been clearly defined. 
Gverexpression of HER-2 / neu in breast and ovarian can- 
cers has been implicated in the development of clinical 
drug resistance, poor prognosis and decreased survival 
[22,23]. The ras family of cellular oncogenes has also been 
found to be frequently expressed in several human solid 
tumors [24], and like HER-2/neu, has been associated 
with aggressive malignant phenotype with poor prognosis 
in prostate tumors [25]. While the role of the activated rus 
gene in drug resistance is not clear in mammalian tumor 
cell lines [26,27] several studies have found positive corre- 
lation with high H-r-us expression and resistance to cis- 
platin and ionizing radiation [28-301. Oncogenes and their 
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products have been reported to effect nuclear processes, 
especially nuclear repair enzymes [31-331. While this was 
not addressed in this report, it is possible that overexpres- 
sion of c-jun which encodes for the major form of AP-1 
transcription factor, like c-&s and in association with 
H-rus and c-myc, may induce either/and or both the 
expressions and activity of DNA repair enzymes. Repair 
enzyme rich tumor cells are known to be resistant to 
cisplatin [34,35] and to alkylating agents, and possibly to 
other DNA damaging agents, e.g., VP-16 and doxorubicin. 
DNA repair-based mechanism of cisplatin resistance and 
drug resistance and the role of oncogenes resistance in 
prostate PC3(R) cells is under investigation in our labora- 
tory. 
In accordance with our previous studies [lo], PC3(R) 
cells are significantly more resistant to a wide variety of 
anticancer drugs, including VP-16 and CDDP than the 
parental PC3 cells. In this study, we found that PC3(R) 
cells show higher expressions of c-myc, c-jun and H-rus 
than the drug-sensitive PC3 cells and that both VP-16 and 
CDDP significantly induced c-myc expression in PC3 and 
PO(R) cells. VP-16 and CDDP treatment caused only a 
small increase in the expression of c-jun gene in sensitive 
PC3 cells, and had no affect on H-rus expression. We have 
also found in this present study that expression of bc12 was 
significantly (2-3-fold) higher in drug-resistant PC3(R) 
cells than PC3 cells. 
We found that both drug-sensitive and drug-resistant 
PC3 cells were arrested in S and G2 phases following 
VP-16 treatment. In contrast, CDDP treatment caused Gl 
and early S phase arrest in both cell lines. The drug-sensi- 
tive PC3 cells, however, were significantly less stable 
during cell cycle arrest than drug-resistant PC3(R) cells 
and showed a marked degradation of the genomic DNA 
into oligonucleosomal size DNA fragments, typical of 
apoptosis. Little or no DNA degradation was observed 
with VP-16 treatment in PC3(R) cells even after 72 h of 
drug treatment. Similarly, no DNA degradation was ob- 
served with CDDP in PC3(R) cells up to 48 h; however, a 
significant DNA degradation was observed with CDDP in 
both cells lines at 72 h. 
The c-myc gene is critical for cellular transformation, 
differentiation and proliferation. Overexpression of c-myc 
results in induction of apoptosis, if combined with growth 
signal arrest by chemotherapeutic drugs. Several recent 
studies have indicated that high levels of bcl2 expression 
inhibits cell death from a wide variety of anticancer drugs 
[36,37] by inhibiting drug-induced apoptosis. Furthermore, 
it has been proposed that bc12 cooperates with c-myc and 
inhibits cell death induced by c-myc [38-401. In this study 
we found that PC3(R) cells both overexpressed c-myc and 
bc12 protein and were significantly resistant to anticancer 
drug. Furthermore, PC3(R) cells did not undergo drug 
induced apoptosis. These observations are consistent with 
the hypothesis that high expression of bc12 protein plays 
an important role in chemoresistance. While several stud- 
ies have shown that c-myc, c-jun and H-r-as expression by 
themselves can confer drug resistance, our studies suggest 
that combinations of these proto-oncogenes and higher 
expression of bc12 may cooperate in the development of 
de novo resistance in the subpopulation of PC3 cells. 
These findings may have clinical implications in the poor 
prognosis observed with prostate tumors. 
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